RecruitingNot ApplicableNCT06506942

The TRICURE EFS Study

The TRICURE EFS TRiCares Topaz Transfemoral TRICUspid Heart Valve REplacement System Early Feasibility Study

Sponsor

TRiCares

Enrollment

15 participants

Start Date

Sep 11, 2024

Study Type

INTERVENTIONAL

Conditions

Cardiovascular Diseases Tricuspid Valve Regurgitation Heart Valve Diseases

Summary

Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Transcatheter Tricuspid Valve Replacement for people with cardiovascular diseases, heart valve diseases, and other related conditions. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscatheter Tricuspid Valve Replacement

Replacement of the tricuspid valve through a transcatheter approach

Locations(10)

Piedmont Healthcare Inc.

Atlanta, Georgia, United States

Northwestern

Chicago, Illinois, United States

University of Michigan Hospital and Health Systems

Ann Arbor, Michigan, United States

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States

Columbia University Medical Center/ NewYork Presbyterian Hospital

New York, New York, United States

Montefiore

The Bronx, New York, United States

The Christ Hospital

Cincinnati, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

St. Paul's Hospital

Vancouver, British Columbia, Canada

St. Michaels Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06506942

Related Trials

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

NCT076130991 location

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

NCT072582902 locations

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT0725624911 locations

Pilot Study to Evaluate a Noninvasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With Conduction Disorders Following TAVI Implantation (IMPROVE Study)

NCT074562801 location

Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care

NCT048771971 location